Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | UBE2N | P61088 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264904 | 0.86 | ALDH1A1 (0.68) | CYP2C9KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL11406404 | 0.86 | ALDH1A1 (0.72) | CYP2C9KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31261492 | 0.85 | CYP2C9 (0.76) | CYP2C9KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL28688451 | 0.85 | CYP2C9 (1.00) | CYP2C9KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL13506227 | 0.84 | ALDH1A1 (0.73) | CYP2C9KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2266253 | 0.81 | UBE2N (0.62) | CYP2C9KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL11389512 | 0.79 | NPC1 (0.67) | KMT2AALDH1A1CYP1A2CYP3A4UBE2N | |
| SCHEMBL2267293 | 0.79 | ALDH1A1 (0.58) | CYP2C9KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL15754423 | 0.78 | RPA1 (0.50) | CYP2C9KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2220616 | 0.78 | ALDH1A1 (0.57) | CYP2C9KMT2AALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | CYP2C9 4808/4885KMT2A 720/4885ALDH1A1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.